In partnership with
🔬TODAY’S BREAKTHROUGH
A large UK Biobank study reveals that proteomic age, based on plasma proteins, strongly predicts disease and mortality, and is influenced by specific genetic variants.
The Discovery:
Analyzing 1,459 plasma proteins from 44,435 participants, researchers built a proteomic aging clock that predicted mortality risk: each one-year increase in proteomic age (beyond chronological age) raised all-cause mortality hazard by 13%. Genetic analysis highlighted BRCA1, TET2, and POLR2A as key drivers of proteomic aging.
The Science:
Proteomic clock: Elastic net regression predicted age with high accuracy (R = 0.94; MAE = 2.3 years).
Disease links: Higher proteomic age was associated with cancer, type 2 diabetes, ischemic heart disease, and earlier menopause.
Mortality risk: People in the oldest 10% of proteomic age had sharply reduced survival compared to peers.
Top proteins: GDF15, EGFR, ITGAV, and SCARF2 were among the strongest contributors; many are linked to cancer and frailty.
Genetics: GWAS revealed 16 loci, but three with widespread effects, BRCA1 (DNA repair), TET2 (DNA demethylation), POLR2A (RNA polymerase II).
Causality: Mendelian randomization showed higher BMI and type 2 diabetes causally accelerate proteomic aging; higher testosterone levels appeared protective in women.
Overlap: Proteomic age acceleration correlated modestly with epigenetic clocks and shorter telomeres.
Your Action:
Support a healthier proteome by maintaining metabolic health: avoid obesity, control blood sugar, and prevent chronic inflammation. Balanced nutrition, exercise, and weight management remain central levers to slow proteomic and biological aging.
Bottom Line:
Proteomic aging clocks reveal hidden disease risks, and genes like BRCA1, TET2, and POLR2A shape how fast our proteins, and bodies age.
Source:
Genetic determinants of proteomic aging. npj Aging. Mörseburg A, Zhao Y, Day FR, et al.
https://doi.org/10.1038/s41514-025-00205-4
How was today’s newsletter?
A Quick Favor:
We kindly ask you to check out the sponsor(s) that made this newsletter possible. Your support helps us continue sharing valuable insights and empowering your wellness journey.
How 433 Investors Unlocked 400X Return Potential
Institutional investors back startups to unlock outsized returns. Regular investors have to wait. But not anymore. Thanks to regulatory updates, some companies are doing things differently.
Take Revolut. In 2016, 433 regular people invested an average of $2,730. Today? They got a 400X buyout offer from the company, as Revolut’s valuation increased 89,900% in the same timeframe.
Founded by a former Zillow exec, Pacaso’s co-ownership tech reshapes the $1.3T vacation home market. They’ve earned $110M+ in gross profit to date, including 41% YoY growth in 2024 alone. They even reserved the Nasdaq ticker PCSO.
The same institutional investors behind Uber, Venmo, and eBay backed Pacaso. And you can join them. But not for long. Pacaso’s investment opportunity ends September 18.
Paid advertisement for Pacaso’s Regulation A offering. Read the offering circular at invest.pacaso.com. Reserving a ticker symbol is not a guarantee that the company will go public. Listing on the NASDAQ is subject to approvals.
LEARN MORE ABOUT OUR WORK
— Capilli Eternal
Disclaimer:
This newsletter is for informational purposes only and does not substitute professional medical advice. Always consult with a healthcare provider before making any changes to your health regimen.